{
  "index": 331,
  "prompt": "\nGiven the following scenario, first consider the actors and stakeholders involved then extrapolate and present as a timeline how the situation might evolve. \nConsider as many multiple possibilities based on possible responses which are to be represented as branches on this timeline. \n\nMake sure that the timeline generated are of **HIGH QUALITY** as defined by the following criteria\n* Plausibility: Economic, financial and political plausibility of each path on the timeline \n    * High: Events are strongly supported by current macro data, institutional knowledge, and have strong analogs in history or system models (e.g., “monetary tightening leads to recession, triggering a political backlash”)\n    * Low: Contains major violations of cause-effect logic, timing, or real-world behavior (e.g., hyperinflation causes interest rate cuts during a currency collapse)\n* Novelty: Creativity/originality in the nodes and paths, are they something you may have overlooked?\n    * High: Demonstrates expert-level creative reasoning. Identifies counterintuitive paths, rare risks, or hidden feedback loops. May challenge conventional wisdom in a grounded way (e.g., “trade war accelerates global realignment of semiconductors via Middle East sovereign wealth capital”). Could lead to edge in investment or policy thinking.\n    * Low: Timeline is linear, obvious, or closely tracks past headlines or boilerplate analysis. No creative branching or exploration.\n* Elaboration: How specific and refined are the occurrences represented by the nodes?\n    * High: Timeline reads like a mini-case study. Each node could stand alone as an actionable insight. Paths show feedback loops, strategic responses, and sector-level granularity (e.g., “Volkswagen reallocates $1.2B R&D from EVs to hybrid tech in response to rare earth prices”). Truly investment-grade thinking.\n    * Low: Nodes are generic (e.g., “market reacts”, “tensions rise”) with no detail on mechanisms, actors, or consequences. Lacks causal clarity.\n* Actionable: Can this timeline inform specific investment actions or hedging strategies?\n    * High: Timeline includes sector impacts, asset class consequences, or opportunities (e.g., “short EU auto suppliers”, “long U.S. rail freight”)\n    * Low: Insightful narrative, but no clear link to tradable instruments or positioning ideas\n\nKeep to the output format below where ascii is used to represent the timeline as a tree. \n\n[Example of Scenario]\nWASHINGTON/DETROIT, April 29 (Reuters) - U.S. President Donald Trump signed a pair of orders to soften the blow of his auto tariffs on Tuesday with a mix of credits and relief from other levies on materials, and his trade team touted its first deal with a foreign trading partner.\nThe developments helped eased some investor worries about the erratic trade policies of Trump as the president visited Michigan, a cradle of the U.S. auto industry, just days before a fresh set of 25% import taxes was set to kick in on automotive components.\n\n[Example of Output]\n{\n  \"id\": \"T0\",\n  \"title\": \"Initial Event\",\n  \"description\": \"German inflation data released at 2.2%\",\n  \"children\": [\n    {\n      \"id\": \"T1A1\",\n      \"title\": \"ECB maintains dovish stance\",\n      \"date_range\": \"May\",\n      \"description\": \"ECB maintains dovish stance, keeps rates low\",\n      \"children\": [\n        {\n          \"id\": \"T1A1.1\",\n          \"title\": \"German banks increase lending\",\n          \"description\": \"German banks benefit from low rates, increase lending\"\n        },\n        {\n          \"id\": \"T1A1.2\",\n          \"title\": \"Euro weakens\",\n          \"description\": \"Euro weakens, boosting exports\"\n        },\n        {\n          \"id\": \"T1A1.3\",\n          \"title\": \"Moderate industrial growth\",\n          \"description\": \"German industry reports moderate growth\"\n        },\n        {\n          \"id\": \"T1A1.4\",\n          \"title\": \"Bundesbank caution\",\n          \"description\": \"Bundesbank signals caution on inflation\",\n          \"children\": [\n            {\n              \"id\": \"T2A1\",\n              \"title\": \"Industry adapts to inflation\",\n              \"date_range\": \"June–August\",\n              \"description\": \"Companies pass on higher costs; unions request wage hikes; consumer shifts emerge\",\n              \"children\": [\n                {\n                  \"id\": \"T3A1\",\n                  \"title\": \"Markets stabilize\",\n                  \"date_range\": \"Q3–Q4\",\n                  \"description\": \"Eurozone growth outlook improves; German stocks outperform\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A1\",\n                      \"title\": \"Global growth stabilizes\",\n                      \"date_range\": \"Q4–2025\",\n                      \"description\": \"Global trade rebounds; emerging markets benefit\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5A1\",\n                          \"title\": \"New normal\",\n                          \"date_range\": \"2025+\",\n                          \"description\": \"Stable growth across EU/US; ECB remains dovish\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1A2\",\n      \"title\": \"ECB tightens monetary policy\",\n      \"date_range\": \"May\",\n      \"description\": \"ECB tightens policy in response to inflation\",\n      \"children\": [\n        {\n          \"id\": \"T1A2.1\",\n          \"title\": \"Euro strengthens\",\n          \"description\": \"Euro strengthens, hurting exports\"\n        },\n        {\n          \"id\": \"T1A2.2\",\n          \"title\": \"Industrial slowdown\",\n          \"description\": \"German industry reports slower growth\"\n        },\n        {\n          \"id\": \"T1A2.3\",\n          \"title\": \"Bundesbank warns\",\n          \"description\": \"Bundesbank warns of inflation risks\"\n        },\n        {\n          \"id\": \"T1A2.4\",\n          \"title\": \"Consumers cut back\",\n          \"description\": \"German consumers cut back on spending\",\n          \"children\": [\n            {\n              \"id\": \"T2A2\",\n              \"title\": \"Industry opposes ECB policy\",\n              \"date_range\": \"June–August\",\n              \"description\": \"Job cuts, political backlash, delayed consumption\",\n              \"children\": [\n                {\n                  \"id\": \"T3A2\",\n                  \"title\": \"Markets unstable\",\n                  \"date_range\": \"Q3–Q4\",\n                  \"description\": \"Growth outlook declines; ECB remains hawkish\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A2\",\n                      \"title\": \"Global recession risk rises\",\n                      \"date_range\": \"Q4–2025\",\n                      \"description\": \"Trade slows; emerging markets struggle\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5A2\",\n                          \"title\": \"Global downturn\",\n                          \"date_range\": \"2025+\",\n                          \"description\": \"Recession conditions persist; ECB maintains rate hikes\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    }\n  ]\n}\n\n[Given Scenario]\nThe global immunotoxins market size was estimated at USD 142.2 million in 2023 and is projected to reach USD 344.7 million by 2034, reflecting a compound annual growth rate (CAGR) of 8.11% during the forecast period of 2024 to 2034. This growth is attributed to the rising global prevalence of various malignancies, increased research and development (R&D) activities, heightened investment and funding, the approval of new immunotoxin therapies, and an increase in collaborations and partnerships. \n\nThe Diphtheria Toxin (DT) segment emerged as the highest revenue-generating segment in the global immunotoxins market in 2023, due to the proven effectiveness of DT-based immunotoxins in targeted cancer therapies. The Pseudomonas Exotoxin segment is anticipated to witness the fastest CAGR during the forecast period, driven by the success of Pseudomonas exotoxin-based therapies in clinical trials and advancements that enhance tumor-targeting capabilities while reducing immunogenicity.\n\nThe therapy development segment accounted for the highest revenue in the global immunotoxins market in 2023, resulting from an increased focus on creating novel immunotoxin-based therapies, substantial investments in research and clinical trials, and a rising demand for targeted cancer treatments. The biomedical research segment is projected to grow at the fastest CAGR during the forecast period, spurred by escalating interest in exploring immunotoxins for new therapeutic applications, increased cancer research funding, and advancements in biotechnology.\n\nNorth America is anticipated to have the highest revenue share during the forecast period, due to the presence of major pharmaceutical and biotechnology companies, advanced healthcare infrastructure, high investment in cancer research, and early adoption of innovative immunotoxin therapies. The Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period, driven by the rising prevalence of cancer, increasing healthcare expenditure, growing biotechnology and pharmaceutical sectors, expanding clinical trial activities, and improvements in healthcare infrastructure.\n\nKey players in the immunotoxins market include Amgen Inc., Eisai Co. Ltd., Genentech (Roche), AbbVie Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Novartis AG, Merck & Co. Inc., Celltech Pharma Ltd., ImmunoGen Inc., BioNTech SE, Macrogenics Inc., Cellerant Therapeutics Inc., Iovance Biotherapeutics Inc., and Zymeworks Inc.\n[Output in JSON]\n",
  "response": "```json\n{\n  \"id\": \"T0\",\n  \"title\": \"Global Immunotoxins Market in 2023\",\n  \"description\": \"The global immunotoxins market is valued at USD 142.2 million, driven by rising cancer prevalence, increased R&D activities, heightened investments, new therapy approvals, and enhanced collaborations.\",\n  \"children\": [\n    {\n      \"id\": \"T1A\",\n      \"title\": \"Breakthrough in Pseudomonas Exotoxin Therapies\",\n      \"date_range\": \"2024-2026\",\n      \"description\": \"Significant advancements in Pseudomonas exotoxin-based therapies improve tumor-targeting and reduce immunogenicity.\",\n      \"children\": [\n        {\n          \"id\": \"T2A1\",\n          \"title\": \"FDA Approves Leading Pseudomonas Exotoxin Therapy\",\n          \"date_range\": \"2025\",\n          \"description\": \"The FDA grants approval for the first Pseudomonas exotoxin-based immunotoxin therapy for metastatic melanoma.\",\n          \"children\": [\n            {\n              \"id\": \"T3A1\",\n              \"title\": \"Market Expansion in North America\",\n              \"date_range\": \"2025-2027\",\n              \"description\": \"Increased adoption of the approved therapy boosts market share in North America.\",\n              \"children\": [\n                {\n                  \"id\": \"T4A1\",\n                  \"title\": \"Investment Opportunity: Biotech Firms Specializing in Pseudomonas Exotoxin\",\n                  \"description\": \"Investors consider long positions in companies leading Pseudomonas exotoxin research and production.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T5A1\",\n                      \"title\": \"Biotech Stocks Surge\",\n                      \"date_range\": \"2026\",\n                      \"description\": \"Stocks of key players like ImmunoGen Inc. and BioNTech SE experience significant growth.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T6A1\",\n                          \"title\": \"Reinvestment into R&D\",\n                          \"description\": \"Profits from stock surges are reinvested into further R&D, fostering continuous innovation.\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            },\n            {\n              \"id\": \"T3A2\",\n              \"title\": \"Global Partnerships Formed\",\n              \"description\": \"North American firms partner with Asia Pacific companies to expand global reach.\",\n              \"children\": [\n                {\n                  \"id\": \"T4A2\",\n                  \"title\": \"Asia Pacific Market Growth\",\n                  \"date_range\": \"2026-2028\",\n                  \"description\": \"Collaborations lead to increased clinical trials and therapy adoption in the Asia Pacific region.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T5A2\",\n                      \"title\": \"Regional Investment Funds Launch\",\n                      \"description\": \"New funds focused on Asia Pacific immunotoxins market attract global investors.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T6A2\",\n                          \"title\": \"Enhanced Healthcare Infrastructure\",\n                          \"description\": \"Improved infrastructure supports the distribution and administration of new therapies.\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T2A2\",\n          \"title\": \"Clinical Trial Setbacks for Competing Therapies\",\n          \"date_range\": \"2025-2026\",\n          \"description\": \"Several competitors face delays or failures in their Pseudomonas exotoxin-based therapy trials.\",\n          \"children\": [\n            {\n              \"id\": \"T3A3\",\n              \"title\": \"Consolidation in the Market\",\n              \"date_range\": \"2026-2027\",\n              \"description\": \"Struggling companies merge or are acquired by stronger players, reducing competition.\",\n              \"children\": [\n                {\n                  \"id\": \"T4A3\",\n                  \"title\": \"Increased Market Share for Leading Firms\",\n                  \"description\": \"Top companies like Novartis AG and Merck & Co. Inc. dominate the market.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T5A3\",\n                      \"title\": \"Strategic Acquisitions\",\n                      \"description\": \"Leading firms acquire smaller biotech companies to enhance their R&D capabilities.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T6A3\",\n                          \"title\": \"Diversified Product Portfolios\",\n                          \"description\": \"Acquisitions lead to a broader range of immunotoxin therapies, attracting more investment.\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            },\n            {\n              \"id\": \"T3A4\",\n              \"title\": \"Shift in Investment Focus\",\n              \"description\": \"Investors redirect funds from failing therapies to more promising segments like Pseudomonas exotoxin-based treatments.\",\n              \"children\": [\n                {\n                  \"id\": \"T4A4\",\n                  \"title\": \"Increased Funding for Successful Therapies\",\n                  \"description\": \"Successful therapies receive more funding, accelerating their development and market penetration.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T5A4\",\n                      \"title\": \"Enhanced Clinical Trial Pipelines\",\n                      \"description\": \"More robust clinical trials lead to faster approvals and wider adoption.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T6A4\",\n                          \"title\": \"Long-term Market Leadership\",\n                          \"description\": \"Leading firms establish a strong foothold, ensuring sustained revenue growth.\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1B\",\n      \"title\": \"Regulatory Hurdles and Safety Concerns\",\n      \"date_range\": \"2024-2027\",\n      \"description\": \"Heightened regulatory scrutiny and safety concerns regarding immunotoxin therapies slow market growth.\",\n      \"children\": [\n        {\n          \"id\": \"T2B1\",\n          \"title\": \"FDA Implements Stricter Approval Processes\",\n          \"date_range\": \"2025\",\n          \"description\": \"The FDA introduces more rigorous testing requirements for immunotoxin therapies.\",\n          \"children\": [\n            {\n              \"id\": \"T3B1\",\n              \"title\": \"Extended Approval Timelines\",\n              \"description\": \"Therapy approval timelines increase, delaying market entry for new products.\",\n              \"children\": [\n                {\n                  \"id\": \"T4B1\",\n                  \"title\": \"Increased R&D Costs\",\n                  \"description\": \"Companies face higher costs to meet regulatory standards, impacting profitability.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T5B1\",\n                      \"title\": \"Selective Investment Strategies\",\n                      \"description\": \"Investors favor companies with robust compliance and safety records.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T6B1\",\n                          \"title\": \"Market Consolidation\",\n                          \"description\": \"Weaker firms exit the market or are acquired by more compliant companies.\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T2B2\",\n          \"title\": \"Safety Concerns and Adverse Events\",\n          \"date_range\": \"2025-2026\",\n          \"description\": \"Reports of adverse events related to immunotoxin therapies raise safety concerns.\",\n          \"children\": [\n            {\n              \"id\": \"T3B2\",\n              \"title\": \"Public Trust Erodes\",\n              \"description\": \"Patients become hesitant to adopt immunotoxin therapies, reducing demand.\",\n              \"children\": [\n                {\n                  \"id\": \"T4B2\",\n                  \"title\": \"Shift to Alternative Therapies\",\n                  \"description\": \"Healthcare providers favor alternative cancer treatments with better safety profiles.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T5B2\",\n                      \"title\": \"Investment Diversification\",\n                      \"description\": \"Investors diversify portfolios away from high-risk immunotoxin therapies.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T6B2\",\n                          \"title\": \"Decreased Market Growth\",\n                          \"description\": \"Slower adoption rates stunt overall market growth.\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            },\n            {\n              \"id\": \"T3B3\",\n              \"title\": \"Regulatory Revisions\",\n              \"description\": \"Regulatory bodies revise guidelines to enhance therapy safety.\",\n              \"children\": [\n                {\n                  \"id\": \"T4B3\",\n                  \"title\": \"Enhanced Monitoring Systems\",\n                  \"description\": \"Implementation of post-market surveillance to monitor therapy efficacy and safety.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T5B3\",\n                      \"title\": \"Long-term Research Investments\",\n                      \"description\": \"Companies invest in long-term studies to demonstrate safety and efficacy.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T6B3\",\n                          \"title\": \"Gradual Market Recovery\",\n                          \"description\": \"Improved safety profiles restore public trust, leading to incremental market recovery.\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1C\",\n      \"title\": \"Technological Innovations Boosting Immunotoxins\",\n      \"date_range\": \"2024-2028\",\n      \"description\": \"Emerging technologies enhance the development and effectiveness of immunotoxin therapies.\",\n      \"children\": [\n        {\n          \"id\": \"T2C1\",\n          \"title\": \"Advancements in Biotechnology Platforms\",\n          \"date_range\": \"2025-2027\",\n          \"description\": \"New biotechnological platforms enable more precise engineering of immunotoxins.\",\n          \"children\": [\n            {\n              \"id\": \"T3C1\",\n              \"title\": \"Enhanced Efficacy and Reduced Side Effects\",\n              \"description\": \"Improved engineering leads to therapies with higher efficacy and fewer side effects.\",\n              \"children\": [\n                {\n                  \"id\": \"T4C1\",\n                  \"title\": \"Increased Clinical Trial Success Rates\",\n                  \"description\": \"Higher success rates in clinical trials accelerate therapy approvals.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T5C1\",\n                      \"title\": \"Rapid Market Penetration\",\n                      \"description\": \"New therapies reach the market faster, driving revenue growth.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T6C1\",\n                          \"title\": \"Investor Confidence Rises\",\n                          \"description\": \"Positive trial outcomes boost investor confidence, leading to increased funding.\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T2C2\",\n          \"title\": \"AI and Machine Learning Integration\",\n          \"date_range\": \"2026-2028\",\n          \"description\": \"Integration of AI and machine learning in the R&D process optimizes immunotoxin design and personalization.\",\n          \"children\": [\n            {\n              \"id\": \"T3C2\",\n              \"title\": \"Personalized Immunotoxin Therapies\",\n              \"description\": \"AI-driven personalization enhances treatment effectiveness for individual patients.\",\n              \"children\": [\n                {\n                  \"id\": \"T4C2\",\n                  \"title\": \"Market Differentiation\",\n                  \"description\": \"Companies offering personalized therapies gain a competitive edge.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T5C2\",\n                      \"title\": \"Premium Pricing Strategies\",\n                      \"description\": \"Personalized therapies command higher prices, increasing profit margins.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T6C2\",\n                          \"title\": \"Attractive Investment Outlook\",\n                          \"description\": \"Higher margins and differentiation make these companies attractive for investment.\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1D\",\n      \"title\": \"Market Expansion and Regional Dynamics\",\n      \"date_range\": \"2024-2030\",\n      \"description\": \"Regional factors influence the growth trajectory of the global immunotoxins market.\",\n      \"children\": [\n        {\n          \"id\": \"T2D1\",\n          \"title\": \"North America Leads Revenue Share\",\n          \"description\": \"Presence of major pharmaceutical companies and advanced healthcare infrastructure maintain North America's leadership.\",\n          \"children\": [\n            {\n              \"id\": \"T3D1\",\n              \"title\": \"Continued Investment in R&D\",\n              \"description\": \"North American firms continue heavy investment in R&D, driving innovation.\",\n              \"children\": [\n                {\n                  \"id\": \"T4D1\",\n                  \"title\": \"Leadership in Therapy Approvals\",\n                  \"description\": \"High number of therapy approvals solidifies North America's market dominance.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T5D1\",\n                      \"title\": \"Investment in North American Biotech ETFs\",\n                      \"description\": \"Investors allocate funds to ETFs focusing on North American biotech firms specializing in immunotoxins.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T6D1\",\n                          \"title\": \"Portfolio Diversification\",\n                          \"description\": \"Enhanced biotech ETFs offer diversified exposure, mitigating individual stock risks.\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T2D2\",\n          \"title\": \"Asia Pacific Rapid Growth\",\n          \"description\": \"Rising cancer prevalence, increased healthcare expenditure, and expanding biotech sectors drive Asia Pacific's fastest CAGR.\",\n          \"children\": [\n            {\n              \"id\": \"T3D2\",\n              \"title\": \"Government Initiatives and Funding\",\n              \"description\": \"Governments in Asia Pacific countries launch initiatives to support biotech innovation and healthcare infrastructure.\",\n              \"children\": [\n                {\n                  \"id\": \"T4D2\",\n                  \"title\": \"Increase in Local Partnerships\",\n                  \"description\": \"Local companies form partnerships with international firms to leverage technology and expertise.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T5D2\",\n                      \"title\": \"Emerging Market Investment Funds\",\n                      \"description\": \"New investment funds focus on Asia Pacific immunotoxins market, attracting global capital.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T6D2\",\n                          \"title\": \"High ROI Potential\",\n                          \"description\": \"Rapid market growth and early-stage investments offer high return on investment opportunities.\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T2D3\",\n          \"title\": \"Europe's Strategic Positioning\",\n          \"description\": \"Europe leverages strong biomedical research and collaborations to maintain a significant market presence.\",\n          \"children\": [\n            {\n              \"id\": \"T3D3\",\n              \"title\": \"Enhanced EU Funding for Biotech\",\n              \"description\": \"The European Union increases funding for biotech research, including immunotoxin therapies.\",\n              \"children\": [\n                {\n                  \"id\": \"T4D3\",\n                  \"title\": \"Growth of European Biotech Hubs\",\n                  \"description\": \"Regions like Germany and Switzerland become biotech hubs, fostering innovation and attracting talent.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T5D3\",\n                      \"title\": \"Investment in European Biotech Stocks\",\n                      \"description\": \"Investors target European biotech companies poised for growth in the immunotoxins sector.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T6D3\",\n                          \"title\": \"Balanced Global Portfolio\",\n                          \"description\": \"Including European biotech stocks enhances portfolio diversification and stability.\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    }\n  ]\n}\n```",
  "processing_time": 46.67611765861511,
  "estimated_prompt_tokens": 2392,
  "response_tokens": 3354
}